GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alivus Life Sciences Ltd (NSE:ALIVUS) » Definitions » EV-to-FCF

Alivus Life Sciences (NSE:ALIVUS) EV-to-FCF : (As of Mar. 28, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Alivus Life Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Alivus Life Sciences's Enterprise Value is ₹125,580 Mil. Alivus Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was ₹0 Mil. Therefore, Alivus Life Sciences's EV-to-FCF for today is .

The historical rank and industry rank for Alivus Life Sciences's EV-to-FCF or its related term are showing as below:

NSE:ALIVUS' s EV-to-FCF Range Over the Past 10 Years
Min: 0   Med: 0   Max: 71.56
Current: 42.29

During the past 6 years, the highest EV-to-FCF of Alivus Life Sciences was 71.56. The lowest was 0.00. And the median was 0.00.

NSE:ALIVUS's EV-to-FCF is ranked worse than
70.67% of 549 companies
in the Drug Manufacturers industry
Industry Median: 23.39 vs NSE:ALIVUS: 42.29

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-28), Alivus Life Sciences's stock price is ₹1061.65. Alivus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹35.930. Therefore, Alivus Life Sciences's PE Ratio (TTM) for today is 29.55.


Alivus Life Sciences EV-to-FCF Historical Data

The historical data trend for Alivus Life Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alivus Life Sciences EV-to-FCF Chart

Alivus Life Sciences Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial - - 10.98 31.66 32.39

Alivus Life Sciences Quarterly Data
Mar19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 32.39 - - -

Competitive Comparison of Alivus Life Sciences's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alivus Life Sciences's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Alivus Life Sciences's EV-to-FCF falls into.


;
;

Alivus Life Sciences EV-to-FCF Calculation

Alivus Life Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=125580.277/0
=

Alivus Life Sciences's current Enterprise Value is ₹125,580 Mil.
Alivus Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alivus Life Sciences  (NSE:ALIVUS) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Alivus Life Sciences's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1061.65/35.930
=29.55

Alivus Life Sciences's share price for today is ₹1061.65.
Alivus Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹35.930.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Alivus Life Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Alivus Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Alivus Life Sciences Business Description

Traded in Other Exchanges
Address
470, Cardinal Gracious Road, 4th Floor, OIA House, Andheri (East), Mumbai, MH, IND, 400 099
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.

Alivus Life Sciences Headlines

No Headlines